nifedipine has been researched along with Idiopathic Pulmonary Fibrosis in 1 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Idiopathic Pulmonary Fibrosis: A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, MX | 1 |
| Tian, YJ | 1 |
| Han, C | 1 |
| Liu, RD | 1 |
| Xie, X | 1 |
| Yuan, Y | 1 |
| Yang, YY | 1 |
| Li, Z | 1 |
| Chen, J | 1 |
| Luo, HB | 1 |
| Wu, Y | 1 |
1 other study available for nifedipine and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
Topics: Animals; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Idiopathic Pulmonary | 2022 |